Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia
| Autor: | Matt Kalaycio, Mukta Arora, Joseph H. Antin, Joerg Halter, Richard T. Maziarz, Wael Saber, Matthew Carabasi, Kwang Woo Ahn, Harry C. Schouten, Vikas Gupta, Ann E. Woolfrey, Mahmoud Aljurf, Brian J. Bolwell, David L. Porter, Ian D. Lewis, Xiaochun Zhu, H. Joachim Deeg, Jean-Yves Cahn, Mary M. Horowitz, Philip L. McCarthy, Gregory A. Hale, Bipin N. Savani, Biju George, Mehdi Hamadani, Steven Z. Pavletic, Jorge E. Cortes, Ed Copelan, Baldeep Wirk, Karen K. Ballen |
|---|---|
| Přispěvatelé: | Mayo Clinic, the Cleveland Clinic Foundation, Cleveland Clinic, St Jude Children's Research Hospital, TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), University Hospital Basel [Basel], Roswell Park Cancer Institute [Buffalo], Division of Haematology, University of Toronto-Princess Margaret Hospital, University of Toronto, Institut d'Astrophysique de Paris (IAP), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction |
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Male
Transplantation Conditioning Neutrophils medicine.medical_treatment Graft vs Host Disease Hematopoietic stem cell transplantation PV MESH: Neutrophils Gastroenterology MESH: Polycythemia Vera 0302 clinical medicine Polycythemia vera Recurrence Cumulative incidence Longitudinal Studies MESH: Longitudinal Studies Polycythemia Vera MESH: Transplantation Conditioning MESH: Middle Aged Hematopoietic Stem Cell Transplantation Hematology Middle Aged 3. Good health MESH: Splenomegaly 030220 oncology & carcinogenesis MESH: Survival Analysis Acute Disease Splenectomy MESH: Acute Disease Female Thrombocythemia Essential Adult medicine.medical_specialty MESH: Myeloablative Agonists Platelet Engraftment MESH: Graft vs Host Disease [SDV.CAN]Life Sciences [q-bio]/Cancer MESH: Splenectomy Article 03 medical and health sciences Internal medicine medicine MESH: Transplantation Homologous Humans Transplantation Homologous Myelofibrosis MESH: Hematopoietic Stem Cell Transplantation Transplantation Neutrophil Engraftment MESH: Humans Essential thrombocythemia business.industry MESH: Adult Myeloablative Agonists medicine.disease Survival Analysis MESH: Male Surgery MESH: Recurrence Splenomegaly MESH: Thrombocythemia Essential business ET MESH: Female 030215 immunology |
| Zdroj: | Biology of Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation, Elsevier, 2012, 18 (9), pp.1446-54. ⟨10.1016/j.bbmt.2012.03.009⟩ Biology of Blood and Marrow Transplantation, 18(9), 1446-1454. Elsevier Science |
| ISSN: | 1083-8791 1523-6536 |
| DOI: | 10.1016/j.bbmt.2012.03.009⟩ |
| Popis: | Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS. American Society for Blood and Marrow Transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect